Condition: IgA Nephropathy (IgAN) · Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
This description comes directly from the study's public registry record.
Weifang Zeng · +8602867258840 · zengwf@haisco.com
Always discuss trial participation with your own doctor first.
| Huangshan City People's Hospital | Huangshan City, Anhui, China | Recruiting |
| The Second Affiliated Hospital of Wannan Medical College | Wuhu, Anhui, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Zhanjiang Central Hospital | Zhanjiang, Guangdong, China | Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| The Second Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| Linyi City People Hospital | Linyi, Shandong, China | Recruiting |
| Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Xijing Hospital | Xi’an, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07390123